ACRS News and Press, Aclaris Therapeutics Inc. From 11/12/19

WAYNE, Pa., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced that management will present at the following conferences: Dr. Neal Walker, President and Chief Exe...

These Penny Stocks Are Galluping Toward New Highs This Month It’s often noticed that investors concentrate on different sectors when it comes to building a stock portfolio. Over the years it has proven to be a sound strategy. When it comes to investing in penny stocks , you should choo...

Aclaris Therapeutics, Inc. (ACRS) Q3 2019 Earnings Conference Call November 7, 2019 5:00 PM ET Company Participants Kamil Ali-Jackson - Chief Legal Officer Neal Walker - President and Chief Executive Officer David Gordon - Chief Medical Officer Frank Ruffo - Chief Financial Off...

Will These 3 Penny Stocks Head Higher in November? Over the years penny stocks have often managed to generate substantial returns for investors. So, investors still look for the next big thing from these cheap stocks. Since penny stocks are generally low priced, there’s the added adva...

Aclaris Therapeutics (NASDAQ: ACRS ): Q3 GAAP EPS of -$1.34 misses by $0.65 . More news on: Aclaris Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Completed Strategic Review and Announced Refocusing of Resources on Immuno-inflammatory Development Pipeline Divested RHOFADE ® (oxymetazoline hydrochloride) cream, 1% Repaid $30 Million Term Loan  Successful Pivotal Phase 3 Clinical Trials of A-101 45% Topical ...

WAYNE, Pa., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it will report financial results for the third quarter 2019, Thursday, November 7 th , after U.S. financ...

Xunlei (NASDAQ: XNET ) +16% . More news on: Xunlei Limited, Reebonz Holding Limited, Aclaris Therapeutics, Inc., Stocks on the move, Read more ...

Aclaris (NASDAQ: ACRS ) has vaulted 19.1% after its postmarket news that its topical wart drug met its goal in a late-stage trial . More news on: Aclaris Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

If approved, A-101 45% Topical Solution would be the first FDA-approved prescription treatment for common warts Highly statistically significant results for the primary efficacy endpoint Highly statistically significant results for all secondary efficacy endpoints Management to host...